Skip to content
Clinical Trials – home
BulgariaBack to Bulgaria

Clinical trials in Gabrovo – page 3

67 clinical trials in Gabrovo, Bulgaria across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gabrovo at a glance
67
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

67 trials in Gabrovo

Open in trial search

Hypertension

Not recruiting

Study on Lorundrostat for Patients with Uncontrolled and Resistant Hypertension

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Lorundrostat
  • Sponsor:Mineralys Therapeutics Inc.

Obesity

Not recruiting

Efficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Metsera Inc.

Obesity

Not recruiting

A study to evaluate the efficacy and safety of MET097 in people with obesity or overweight.

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Metsera Inc.

Psoriasis

Not recruiting

Comparison of zasocitinib and deucravacitinib in adults with moderate to severe plaque psoriasis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Takeda Development Center Americas Inc.

Psoriasis

Not recruiting

Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Influenza

Not recruiting

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
  • Sponsor:Seqirus UK Limited

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Envudeucitinib
  • Sponsor:Alumis Inc.

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of Zasocitinib for Patients with Moderate-to-Severe Plaque Psoriasis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.

Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Roflumilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Study of Olezarsen (ISIS 678354) in Patients with Severe Hypertriglyceridemia: Testing Effects on Triglyceride Levels

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Other cities in Bulgaria

The busiest research cities in the country

All 53 cities in Bulgaria

Clinical research in Gabrovo

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on advanced cancer treatments, including studies for breast cancer, prostate cancer, lung cancer, and bladder cancer. Research encompasses both targeted therapies and combination treatments.

  • Metastatic breast cancer treatments
  • Advanced non-small cell lung cancer therapies
  • Prostate cancer interventions
  • Bladder cancer treatments

Special emphasis on developing targeted therapies for specific genetic mutations and combinations with immunotherapy.

02 Respiratory Medicine

Comprehensive research into respiratory conditions, with particular focus on chronic diseases and their management through innovative therapeutic approaches.

  • Asthma management studies
  • COPD treatment evaluations
  • Maintenance therapy optimization

Trials evaluate both single and combination therapies for improving lung function and quality of life.

03 Dermatology Studies

Advanced research in chronic skin conditions, investigating new therapeutic options for various dermatological disorders.

  • Plaque psoriasis treatments
  • Atopic dermatitis therapies
  • Long-term safety evaluations

Focus on developing both topical and systemic treatments for moderate to severe cases.

04 Cardiovascular Research

Innovative studies addressing heart conditions and related metabolic disorders, including new approaches to managing cholesterol and heart failure.

  • Heart failure treatments
  • Cholesterol management
  • Hypertriglyceridemia therapies

Emphasis on both preserved and reduced ejection fraction heart failure treatments.

05 Infectious Diseases

Research focusing on viral infections and preventive medicine, including vaccine development and infection management.

  • Influenza vaccine studies
  • Varicella vaccination
  • Urinary tract infection treatments

Special attention to vaccine safety and efficacy in various age groups.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.